Qiagen (QGEN) Getting Somewhat Positive Media Coverage, Analysis Finds

News coverage about Qiagen (NASDAQ:QGEN) has trended somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Qiagen earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.9679840450792 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Shares of NASDAQ:QGEN opened at $37.14 on Tuesday. Qiagen has a 1-year low of $30.20 and a 1-year high of $37.61. The company has a current ratio of 5.07, a quick ratio of 4.59 and a debt-to-equity ratio of 0.69.

Get Qiagen alerts:

Qiagen (NASDAQ:QGEN) last announced its quarterly earnings data on Wednesday, May 2nd. The company reported $0.26 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.02. The firm had revenue of $343.60 million during the quarter, compared to analysts’ expectations of $339.30 million. Qiagen had a return on equity of 11.74% and a net margin of 2.85%. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.22 EPS. equities analysts expect that Qiagen will post 1.34 EPS for the current fiscal year.

A number of research analysts recently issued reports on QGEN shares. TheStreet raised Qiagen from a “c+” rating to a “b” rating in a report on Friday, May 25th. Commerzbank reaffirmed a “buy” rating on shares of Qiagen in a report on Thursday, May 3rd. BidaskClub raised Qiagen from a “hold” rating to a “buy” rating in a report on Thursday, May 3rd. Deutsche Bank reaffirmed a “buy” rating and issued a price target (up from ) on shares of Qiagen in a report on Tuesday, April 24th. Finally, Goldman Sachs Group reaffirmed a “buy” rating on shares of Qiagen in a report on Wednesday, May 16th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the stock. Qiagen presently has a consensus rating of “Hold” and a consensus price target of $35.55.

Qiagen Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.